Life Sciences
A strong team of seasoned professionals and talented specialists form the bedrock of KPCB’s Life Sciences investing strategy — a focus area for our firm since its inception in 1972. This depth of commitment and experience has earned us a reputation as a world-class venture capital firm in the medical, healthcare and biotech arenas.
At KPCB, we proactively partner with scientists, healthcare providers, thought leaders, policy experts, entrepreneurs and organizations to foster change through innovation. We consistently seek out opportunities to help companies catapult their good ideas from “bench to bedside” effectively.
Over the years, we’ve helped build more than 100 life sciences companies working to improve the health and lives of millions of people worldwide. Our portfolio companies have developed innovative technologies and products in therapeutic and medical devices, drugs, vaccines, personalized medicine, diagnostics and healthcare IT and services. We’ve worked in tandem with our invested companies to pioneer recombinant DNA, monoclonal antibodies, molecular diagnostics, implantable therapeutic devices, combinatorial chemistry, non-viral vaccines, laser treatments and protein drug discovery.
With our Life Sciences practice, business success is part of our DNA.
Partners
-
Brook Byers Investment Partner Life Sciences -
Isaac Ciechanover Investment Partner Life Sciences -
James Huang Investment Partner China, Life Sciences -
Joseph Lacob Investment Partner Life Sciences -
Lawrence Leisure Operating Partner Life Sciences -
Dana Mead Investment Partner Life Sciences -
Thomas Monath Investment Partner Life Sciences -
Beth Seidenberg Investment Partner Life Sciences -
Risa Stack Investment Partner Life Sciences